Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
| ▸ | TUBB | P07437 | 1/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | SDHB | P21912 | 2/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659202 | 0.85 | NPC1 (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3878179 | 0.83 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6216482 | 0.83 | KDM4E (0.47) | NPC1RAB9ASMN1; SMN2NPSR1CA12 | |
| SCHEMBL10667889 | 0.82 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4195184 | 0.82 | LMNA (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9264129 | 0.82 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4859800 | 0.81 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL125591 | 0.81 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30480593 | 0.81 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4476468 | 0.81 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-12495798-B2 | Nicotinamide compound and herbicidal composition comprising compound | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-12-16 | — | — | US | disclosed |
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-10-16 | — | — | US | disclosed |
| EP-4567036-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| EP-4556473-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | disclosed |
| EP-4341255-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-0502740-B1 | Herbicidal pyridine sulfonamide | DU PONT (US) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997046530-A1 | HERBICIDAL PYRIDINYL AND PYRAZOLYLPHENYL KETONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| US-5440043-A | To prepare chemcial intermediates for sulfonylurea herbicides; reacting enones with acetonitrile derivatives under basic conditions, cyclizing under acidic conditions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-08-08 | — | — | US | disclosed |
| US-5393734-A | Herbicidal pyridine sulfonamide | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| US-5332823-A | Herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0575503-A1 | HERBICIDAL PYRIDINE SULFONAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5235060-A | CERTAIN THREE COMPONENT IONIC SUBSTITUTED PYRIDINE COMPOUNDS AS INTERMEDIATES FOR PREPARATION AS HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0522392-A1 | Substituted pyridines and a process for their preparation | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-13 | — | — | EP | disclosed |
| WO-1992015576-A1 | HERBICIDAL PYRIDINE SULFONAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
| EP-0502740-A1 | Herbicidal pyridine sulfonamide | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | TUBB4A 4048/4885TUBB 3548/4885TUBA3C 4296/4885 |
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | GLP1R, GCGR, GIPR | TUBB4A 4875/4885TUBB 4862/4885TUBA3C 4623/4885 |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | TUBB4A 4642/4885TUBB 4631/4885TUBA3C 4007/4885 |
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | TUBB4A 4501/4885TUBB 4295/4885TUBA3C 4621/4885 |
| US-12495798-B2 | Nicotinamide compound and herbicidal composition comprising compound | NAMPT, SIRT1, SIRT6 | TUBB4A 1186/4885TUBB 790/4885TUBA3C 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.